Linked Life Data

21432860

Source:http://linkedlifedata.com/resource/pubmed/id/21432860

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21432860rdf:typepubmed:Citationlld:pubmed
pubmed-article:21432860lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:21432860lifeskim:mentionsumls-concept:C0001779lld:lifeskim
pubmed-article:21432860lifeskim:mentionsumls-concept:C0006684lld:lifeskim
pubmed-article:21432860lifeskim:mentionsumls-concept:C1522496lld:lifeskim
pubmed-article:21432860lifeskim:mentionsumls-concept:C0022661lld:lifeskim
pubmed-article:21432860lifeskim:mentionsumls-concept:C0160420lld:lifeskim
pubmed-article:21432860lifeskim:mentionsumls-concept:C0403447lld:lifeskim
pubmed-article:21432860lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:21432860lifeskim:mentionsumls-concept:C0441766lld:lifeskim
pubmed-article:21432860lifeskim:mentionsumls-concept:C0034634lld:lifeskim
pubmed-article:21432860lifeskim:mentionsumls-concept:C1366622lld:lifeskim
pubmed-article:21432860lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:21432860lifeskim:mentionsumls-concept:C2349209lld:lifeskim
pubmed-article:21432860lifeskim:mentionsumls-concept:C1549649lld:lifeskim
pubmed-article:21432860lifeskim:mentionsumls-concept:C0910022lld:lifeskim
pubmed-article:21432860pubmed:issue6lld:pubmed
pubmed-article:21432860pubmed:dateCreated2011-6-10lld:pubmed
pubmed-article:21432860pubmed:abstractTextThere is a growing body of evidence that advanced glycation end products (AGE) and their receptor (RAGE) system are implicated in chronic kidney disease (CKD). We have previously found that a long-acting calcium channel blocker, azelnidipine, but not amlodipine, improves renal injury in CKD patients. However, little is known about the effect of azelnidipine on the AGE-RAGE axis in humans. In this study, we examined whether azelnidipine addition could have renoprotective properties in hypertensive CKD patients by reducing serum levels of AGE and soluble form of RAGE (sRAGE). Thirty nondiabetic stage I or II CKD patients who had already been treated with angiotensin II receptor blockers were enrolled in this study.lld:pubmed
pubmed-article:21432860pubmed:languageenglld:pubmed
pubmed-article:21432860pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21432860pubmed:citationSubsetIMlld:pubmed
pubmed-article:21432860pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21432860pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21432860pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21432860pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21432860pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21432860pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21432860pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21432860pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21432860pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21432860pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21432860pubmed:statusMEDLINElld:pubmed
pubmed-article:21432860pubmed:monthJunlld:pubmed
pubmed-article:21432860pubmed:issn1932-8737lld:pubmed
pubmed-article:21432860pubmed:authorpubmed-author:YamagishiSho-...lld:pubmed
pubmed-article:21432860pubmed:authorpubmed-author:TakeuchiMasay...lld:pubmed
pubmed-article:21432860pubmed:authorpubmed-author:NakamuraTsuka...lld:pubmed
pubmed-article:21432860pubmed:authorpubmed-author:KoideHikaruHlld:pubmed
pubmed-article:21432860pubmed:authorpubmed-author:UedaYoshihiko...lld:pubmed
pubmed-article:21432860pubmed:authorpubmed-author:SatoEiichiElld:pubmed
pubmed-article:21432860pubmed:authorpubmed-author:KawagoeYasuhi...lld:pubmed
pubmed-article:21432860pubmed:authorpubmed-author:FujiwaraNobuh...lld:pubmed
pubmed-article:21432860pubmed:copyrightInfo© 2011 Wiley Periodicals, Inc.lld:pubmed
pubmed-article:21432860pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21432860pubmed:volume34lld:pubmed
pubmed-article:21432860pubmed:ownerNLMlld:pubmed
pubmed-article:21432860pubmed:authorsCompleteYlld:pubmed
pubmed-article:21432860pubmed:pagination372-7lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:meshHeadingpubmed-meshheading:21432860...lld:pubmed
pubmed-article:21432860pubmed:year2011lld:pubmed
pubmed-article:21432860pubmed:articleTitleCalcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease.lld:pubmed
pubmed-article:21432860pubmed:affiliationDivision of Nephrology, Department of Internal Medicine, Shinmatsudo Central General Hospital, Matsudo, Japan.lld:pubmed
pubmed-article:21432860pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21432860pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:21432860pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:21432860pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:177entrezgene:pubmedpubmed-article:21432860lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21432860lld:entrezgene